Malignancy and Cardiovascular Risk Assessment Using the Consortium of Rheumatology Researchers of North America Registry (Corrona) as an External Comparator for Tofacitinib-Exposed Patients within the Rheumatoid Arthritis BID Clinical Trial Program: A Comparative Post-Approval Safety Study (Matched Analysis for Xeljanz with Corrona)

First published 04/04/2018

Last updated 22/02/2024

EU PAS number:

EUPAS23344

Study

Finalised

Documents

Study protocol

Initial protocol

A3921204_PROTOCOL_Final_9Nov2017

English (2.9 MB - PDF)View document

Updated protocol

A3921204_PROTOCOL and APPROVAL AMENDMENT 3_18May2020_

First published: 22/02/2024

English (2.69 MB - PDF)View document

Study results

CT24-WI-GL15-RF01 1.0 NI Study Report Abstract 09 March 2021

English (1.21 MB - PDF)View document

Study report

CT24-WI-GL15-RF02 2.0 NI Study Report 09 March 2021 (1)

English (2.95 MB - PDF)View document

Other information

ENCePP Seal

ENCePP Seal documents

Conflicts of interest of investigators

DoI_EUPAS23344

English (4.67 MB - PDF)View document

Secondary tabs